Search - tctmd.com

Displaying 81 - 100 of 146

Sort: Relevancy | Date

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

March 22, 2022

Guideline-Directed Therapies Underused in Frail HF Patients

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

March 11, 2022

FDA Approves Empagliflozin for Treatment of HFpEF

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

February 07, 2022

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

July 09, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

Less Cancer Among HF Patients Taking Statins, Registry Shows

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

May 27, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

FDA Approves Dapagliflozin for CKD Patients

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.